Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

Por Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Publicado no Onco Targets Ther (2015)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

Por Sato, Yasuyoshi, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Publicado no Onco Targets Ther (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

Por Ohhara, Yoshihito, Suenaga, Mitsukuni, Matsusaka, Satoshi, Shinozaki, Eiji, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Yamaguchi, Toshiharu
Publicado no Drug Des Devel Ther (2015)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Shinozaki, Eiji, Matsusaka, Satoshi, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Publicado no Drug Des Devel Ther (2015)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report

Por Osumi, Hiroki, Matsusaka, Satoshi, Shinozaki, Eiji, Suenaga, Mitsukuni, Mingyon, Mun, Saiura, Akio, Ueno, Masashi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado em 2013

Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of...

Por OBA, MASARU, CHIN, KEISHO, KAWAZOE, YOSHIMASA, TAKAGI, KOICHI, OGURA, MARIKO, SHINOZAKI, EIJI, SUENAGA, MITSUKUNI, MATSUSAKA, SATOSHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado em 2011

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

Por OBA, MASARU, CHIN, KEISHO, KAWAZOE, YOSHIMASA, TAKAGI, KOICHI, OGURA, MARIKO, SHINOZAKI, EIJI, SUENAGA, MITSUKUNI, MATSUSAKA, SATOSHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado em 2011

Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

Por KUBOKI, YASUTOSHI, MIZUNUMA, NOBUYUKI, OZAKA, MASATO, OGURA, MARIKO, SUENAGA, MITSUKUNI, SHINOZAKI, EIJI, MATSUSAKA, SATOSHI, CHIN, KEISHOU, MATSUURA, MASAAKI, HATAKE, KIYOHIKO
Publicado em 2011

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chem...

Por Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Kumekawa, Yosuke, Ogura, Mariko, Ozaka, Masato, Matsusaka, Satoshi, Chin, Keisho, Yamamoto, Noriko, Mizunuma, Nobuyuki
Publicado no BMC Cancer (2015)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

Por Suenaga, Mitsukuni, Fujimoto, Yoshiya, Matsusaka, Satoshi, Shinozaki, Eiji, Akiyoshi, Takashi, Nagayama, Satoshi, Fukunaga, Yosuke, Oya, Masatoshi, Ueno, Masashi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit

Por Bando, Hideaki, Yoshino, Takayuki, Shinozaki, Eiji, Nishina, Tomohiro, Yamazaki, Kentaro, Yamaguchi, Kensei, Yuki, Satoshi, Kajiura, Shinya, Fujii, Satoshi, Yamanaka, Takeharu, Tsuchihara, Katsuya, Ohtsu, Atsushi
Publicado em 2013

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Por Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Wakatsuki, Takeru, Horiike, Yuki, Matsusaka, Satoshi, Dan, Shingo, Shinozaki, Eiji, Seimiya, Hiroyuki, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Yamaguchi, Toshiharu
Publicado no Oncotarget (2016)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Por Nakayama, Izuma, Shinozaki, Eiji, Matsushima, Tomohiro, Wakatsuki, Takeru, Ogura, Mariko, Ichimura, Takashi, Ozaka, Masato, Takahari, Daisuke, Suenaga, Mitsukuni, Chin, Keisho, Mizunuma, Nobuyuki, Yamaguchi, Kensei
Publicado no BMC Cancer (2017)

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

Por OSUMI, HIROKI, SHINOZAKI, EIJI, OSAKO, MASAHIKO, KAWAZOE, YOSHIMASA, OBA, MASARU, MISAKA, TAKAHARU, GOTO, TAKASHI, KAMO, HITOMI, SUENAGA, MITSUKUNI, KUMEKAWA, YOSUKE, OGURA, MARIKO, OZAKA, MASATO, MATSUSAKA, SATOSHI, CHIN, KEISHO, HATAKE, KIYOHIKO, MIZUNUMA, NOBUYUKI
Publicado no Mol Clin Oncol (2015)